Government
Novartis, Novartis Hellas and Alcon Inc. have agreed to pay a total of more than $346 million to settle bribery charges under the Foreign Corrupt Practices Act (FCPA), which is a U.S. anti-bribery law.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
Regeneron Pharmaceuticals said it will vigorously defend federal charges that it was involved in a kickback scheme to bolster sales of its blockbuster macular degeneration drug, Eylea.
COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.
Speaking before Congress on Tuesday, Dr. Anthony Fauci urged people to adopt strategies that involve wearing a mask in public, maintaining social distance and avoiding large gatherings of people.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
The U.S. Food and Drug Administration greenlit Karyopharm Therapeutics’ Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) under accelerated approval.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.
Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration (FDA) has a busy two-week period coming up for drug approvals. Here’s a look.
Crysvita is a drug developed by Ultragenyx Pharmaceutical and Tokyo-based Kyowa Kirin Co. Ltd., a specialty pharmaceutical company.
PRESS RELEASES